The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Imipenem and Cilastatin
Imipenem and Cilastatin Sodium · IMIPENEM 500 mg/20mL; CILASTATIN SODIUM 500 mg/20mL · Injection, Powder, For Solution · Intravenous · Fresenius Kabi USA, LLC
NDC 63323-0322-93 · 25 VIAL, SINGLE-DOSE in 1 CARTON / 20 mL in 1 VIAL, SINGLE-DOSE · ANDA · View full market →
Medicare Part D
All Part D pricing →Matched to CMS's representative package for this drug (NDC 63323-0322-25) — same generic, strength, and dosage form. CMS prices one NDC per drug concept, not every package.
ⓘ How this was built
Data sources
- CMS quarterly Prescription Drug Plan Formulary & Pricing files (SPUF)
Method
Negotiated 30-day point-of-sale unit prices and formulary terms aggregated across every unsuppressed Part D and MA-PD plan for the quarter shown. Point of sale means gross of confidential rebates. CMS publishes one representative NDC per drug concept (RxCUI) rather than every package, so these figures come from CMS's representative package for the same drug — matched on generic name, strength, and dosage form. Estimated from MedPAC's program-wide rebate aggregates (June 2023: DIR = 29% of gross Part D spending; brand rebates ≈ 25–40% of gross, generics minimal). Actual rebates are confidential and vary widely by drug — this is a range, not a fact about this drug.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
Plans pay at point of saleⓘ
$19.49per unit
middle half $16.19–$22.01 · 5,433 plans · Apr 1, 2026
Est. net of rebatesⓘ
≈ $19.49
generic — rebates are minimal, so net ≈ gross
Coverage & restrictions
99%of plans cover it
tier 4 · prior auth 2% · step therapy 0% · qty limit 0%
*No drug-level rebate is public — the estimate applies MedPAC's program-wide brand rebate range to this drug's gross price. Tracked here for 10 quarters since 2024.
NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$280.35
Reported to Texas DSHS · 2026 annual filing · Novaplus/Fresenius Kabi
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicare Part B (ASP)
Payment limit per 250 MG
$6.517
HCPCS J0743 · Jul 1, 2026 quarter · typically ASP + 6%
Medicaid spend (2025)
$5,870
12 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- Acs Dobfar SpaItalymanufacture
- Zambon Switzerland LtdSwitzerlandmanufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- ANDA090577
- TE code
- AP
- Approval date
- Dec 21, 2011
- Patents / exclusivity
- None on file
Shortage history
- Planned discontinuation — Primaxin, Injection, 500mg (NDC 0006-3516-59)Jan 8, 2026
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Imipenem and Cilastatin Sodium (Injection, Powder, For Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Fresenius Kabi USA, LLC | IMIPENEM 500 mg/20mL; CILASTATIN SODIUM 500 mg/20mL | Jul 22, 2026 | Sep 3, 2026 |
| Merck Sharp & Dohme LLC | IMIPENEM 500 mg/100mL; CILASTATIN SODIUM 500 mg/100mL | Jul 22, 2026 | Sep 2, 2026 |
| Fresenius Kabi USA, LLC | IMIPENEM 250 mg/20mL; CILASTATIN SODIUM 250 mg/20mL | Jul 22, 2026 | Aug 28, 2026 |
| Fresenius Kabi USA, LLC | CILASTATIN SODIUM 250 mg/20mL; IMIPENEM 250 mg/20mL | Jul 15, 2026 | Jul 18, 2026 |
| Fresenius Kabi USA, LLC | CILASTATIN SODIUM 500 mg/20mL; IMIPENEM 500 mg/20mL | Jul 15, 2026 | Jul 15, 2026 |
| Merck Sharp & Dohme LLC | CILASTATIN SODIUM 500 mg/100mL; IMIPENEM 500 mg/100mL | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Imipenem and Cilastatin — NDC 63323-0322-93," retrieved September 3, 2026, https://drugdashboards.com/drug/63323032293.
Free to cite with attribution — see how the data is put together.